Before You Treat: Why Skin Lesion Assessment Matters

As cosmetic medicine and aesthetic technology continue to evolve, more patients than ever are seeking treatments designed to improve skin quality, reduce pigmentation, tighten skin, remove vascular lesions, or reverse visible signs of ageing.

• Laser treatments
• IPL
• RF microneedling
• Chemical resurfacing
• Pigment correction
• Tattoo removal

Energy-based treatments are now widely available across private clinics throughout the UK. For many patients, these treatments are safe, effective, and transformative. However, there is an important clinical reality that is often overlooked: not every lesion in a treatment area is benign, and not every suspicious lesion is recognised before treatment begins.

The challenge with skin lesions in aesthetic practice

Many skin cancers — particularly early melanoma — can appear deceptively subtle. Some may resemble freckles, sun spots, seborrhoeic keratoses, post-inflammatory pigmentation, vascular lesions, or otherwise “normal” moles. In early stages, malignant lesions may not immediately appear alarming to the naked eye. This is one reason why dermoscopy has become such an important part of modern skin lesion assessment.

Cancer Research UK notes that dermoscopy allows clinicians to examine skin lesions in far greater detail than visual inspection alone. NICE guidance similarly recommends urgent suspected cancer referral when dermoscopy findings raise suspicion for melanoma.

Why this matters before cosmetic treatment

The concern is not simply whether a lesion is eventually diagnosed. Timing matters. If a suspicious lesion is overlooked and cosmetic treatment proceeds first, the clinical picture can become significantly more complicated.

Energy-based treatments may alter pigmentation, vascularity, surface architecture, inflammation, or visible border definition. This can make future assessment more difficult, and in some cases visible warning signs may become partially obscured following treatment. Delayed recognition of melanoma can have serious consequences. The NHS highlights that melanoma is a skin cancer capable of spreading to other parts of the body, and that early diagnosis remains critically important.

The issue is rarely negligence

In many clinics, lesion assessment happens informally — often through a quick visual check, a brief conversation, or a judgement call. Sometimes the lesion is recognised, sometimes it is assumed to be benign, and sometimes it is not noticed at all.

This is not necessarily because practitioners are careless. It is because aesthetic medicine increasingly intersects with dermatology while the volume of patients with complex skin presentations continues to rise. Many aesthetic practitioners are highly experienced in cosmetic treatments, but identifying early melanoma requires a very different clinical skillset. Even within healthcare, melanoma diagnosis can be challenging.

The growing role of dermoscopy

Dermoscopy has become one of the most important tools in skin lesion assessment. It allows clinicians to visualise structures beneath the skin surface that cannot usually be seen with the naked eye. This improves assessment of pigment networks, asymmetry, vascular patterns, regression structures, and other morphological features associated with malignancy.

Scottish melanoma guidance recommends dermoscopic assessment of suspicious pigmented lesions as part of specialist evaluation pathways. Increasingly, dermoscopy is also being integrated into teledermatology and digital triage pathways throughout the NHS.

Why structured assessment matters

The key issue is not whether every lesion should be referred urgently, as that would overwhelm specialist services. The issue is ensuring lesions are assessed in a structured and clinically defensible way before treatment decisions are made.

Structured lesion assessment introduces consistency into clinical workflows. This may include standardised image capture, dermoscopic imaging, documented lesion history, risk-factor screening, structured triage, and appropriate escalation where necessary. Importantly, structured assessment does not replace clinician judgement — it supports it.

The medico-legal reality

As advanced treatments become more accessible, expectations around clinical governance are also changing. If a suspicious lesion is treated cosmetically before appropriate assessment, questions may later arise regarding recognition, documentation, consent, referral decisions, and overall clinical process.

This is particularly relevant in settings where multiple practitioners may be involved in patient care. Aesthetic clinics are no longer simply treatment environments. Increasingly, they are becoming frontline skin-contact services, and with that comes additional clinical responsibility.

The future of aesthetic practice

Modern aesthetic practice is moving towards greater integration of governance, documentation, dermoscopy, and structured triage. Not because every lesion is dangerous, but because variation in lesion assessment creates risk.

The goal is not to turn aesthetic clinics into dermatology departments. The goal is to ensure that lesions are assessed appropriately before cosmetic intervention takes place. That protects patients, practitioners, clinics, and referral pathways alike.

Final thoughts

Most lesions encountered in aesthetic practice will ultimately prove benign. However, melanoma does not always announce itself clearly. When uncertainty exists, structure matters, because patient safety should begin before treatment starts — not after concerns are identified later.

Patient safety should begin before treatment starts —
not after concerns are identified later.

References

1. Cancer Research UK. (2024). Dermoscopy and skin cancer assessment. Cancer Research UK.
2. Cancer Research UK. (2024). Referral to a specialist for melanoma skin cancer. Cancer Research UK.
3. Chuchu, N., Dinnes, J., Takwoingi, Y., Matin, R., Bayliss, S. E., Davenport, C., & Deeks, J. J. (2018). Teledermatology for diagnosing skin cancer in adults. Cochrane Database of Systematic Reviews, 2018(12), CD013193.
4. Dinnes, J., Deeks, J. J., Chuchu, N., Saleh, D., Bayliss, S. E., Patel, L., Davenport, C., & Matin, R. (2018). Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. Cochrane Database of Systematic Reviews, 2018(12), CD011902.
5. National Institute for Health and Care Excellence. (2022). Suspected cancer: Recognition and referral (NG12). NICE.
6. National Institute for Health and Care Excellence. (2022). Melanoma: Assessment and management (NG14). NICE.
7. NHS England. (2022). Suspected skin cancer two week wait pathway optimisation guidance. NHS England.
8. NHS England. (2023). Skin cancer timed diagnostic pathway. NHS England.
9. NHS England. (2023). Faster diagnosis standard. NHS England.
10. NHS UK. (2024). Melanoma skin cancer. NHS.
11. Scottish Intercollegiate Guidelines Network. (2023). Cutaneous melanoma guideline and diagnostic indicators. NHS Scotland.
12. The British Association of Dermatologists. (2021). Quality standards for teledermatology and skin cancer pathways. British Association of Dermatologists.
13. World Health Organization. (2023). Skin cancers. World Health Organization.